AnaptysBio Company Insiders
| ANAB Stock | USD 19.87 0.04 0.20% |
AnaptysBio's insiders are aggressively selling. The analysis of the overall insider sentiment regarding AnaptysBio suggests that all insiders are panicking. AnaptysBio employs about 117 people. The company is managed by 24 executives with a total tenure of roughly 109 years, averaging almost 4.0 years of service per executive, having 4.88 employees per reported executive.
| Hamza Suria CEO President CEO, Director |
AnaptysBio's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-03-25 | Daniel Faga | Disposed 3000 @ 21.42 | View | ||
| 2024-03-22 | Daniel Faga | Disposed 145940 @ 22.78 | View | ||
| 2024-02-16 | Eric J Loumeau | Disposed 5000 @ 25 | View | ||
| 2024-01-30 | Dennis Mulroy | Disposed 3065 @ 23.63 | View | ||
| 2024-01-08 | Paul F Lizzul | Disposed 2554 @ 21.81 | View | ||
| 2023-11-22 | Eric J. Loumeau | Disposed 882 @ 14.19 | View | ||
| 2023-09-18 | Eric J Loumeau | Disposed 3895 @ 19.32 | View | ||
| 2023-09-14 | Paul F Lizzul | Disposed 2105 @ 19.48 | View |
Monitoring AnaptysBio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
AnaptysBio |
AnaptysBio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AnaptysBio's future performance. Based on our forecasts, it is anticipated that AnaptysBio will maintain a workforce of about 120 employees by May 2024.AnaptysBio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1847) % which means that it has lost $0.1847 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9344) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.42. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.5 M, whereas Total Assets are forecasted to decline to about 354.3 M.As of April 19, 2024, Common Stock Shares Outstanding is expected to decline to about 21 M. The current year's Net Loss is expected to grow to about (110.1 M)
AnaptysBio Workforce Comparison
AnaptysBio is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 1,250. AnaptysBio holds roughly 117 in number of employees claiming about 9% of equities under Health Care industry.
AnaptysBio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AnaptysBio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.9286 | 27 | 14 | 1,106,535 | 558,136 |
| 2023-09-01 | 0.875 | 7 | 8 | 37,846 | 32,105 |
| 2022-09-01 | 3.0 | 3 | 1 | 36,000 | 523.00 |
| 2022-06-01 | 2.0 | 8 | 4 | 1,388,974 | 1,340,120 |
| 2021-12-01 | 0.8667 | 13 | 15 | 131,381 | 223,231 |
| 2021-09-01 | 1.0 | 1 | 1 | 10,000 | 10,000 |
| 2021-06-01 | 7.0 | 7 | 1 | 378,800 | 10,000 |
| 2021-03-01 | 8.5 | 17 | 2 | 3,691,784 | 20,000 |
| 2020-12-01 | 0.6667 | 2 | 3 | 48,958 | 1,416,747 |
| 2020-03-01 | 4.0 | 8 | 2 | 86,000 | 20,000 |
| 2019-12-01 | 3.0 | 6 | 2 | 535,802 | 56,202 |
| 2019-09-01 | 3.0 | 3 | 1 | 25,768 | 0.00 |
| 2019-06-01 | 0.2 | 2 | 10 | 20,060 | 52,548 |
| 2019-03-01 | 1.5714 | 11 | 7 | 200,075 | 212,150 |
| 2018-12-01 | 0.2222 | 6 | 27 | 169,363 | 466,224 |
| 2018-09-01 | 1.0 | 4 | 4 | 190,493 | 150,493 |
| 2018-06-01 | 0.25 | 3 | 12 | 355,306 | 4,472,452 |
| 2018-03-01 | 13.0 | 13 | 1 | 183,990 | 16,483 |
| 2017-09-01 | 0.2727 | 3 | 11 | 76,305 | 1,533,927 |
| 2017-03-01 | 0.6087 | 42 | 69 | 14,848,215 | 18,629,677 |
AnaptysBio Notable Stakeholders
An AnaptysBio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AnaptysBio often face trade-offs trying to please all of them. AnaptysBio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AnaptysBio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Hamza Suria | President CEO, Director | Profile | |
| Dominic Piscitelli | CFO | Profile | |
| Nicholas Lydon | Independent Director | Profile | |
| James Schoeneck | Independent Director | Profile | |
| John Schmid | Independent Director | Profile | |
| Ware | Independent Director | Profile | |
| Dennis Fenton | Independent Director | Profile | |
| James Topper | Independent Director | Profile | |
| Carol Gallagher | Independent Director | Profile | |
| Hollings Renton | Lead Independent Director | Profile | |
| Matthew Moyle | Chief Scientific Officer | Profile | |
| Martin Dahl | Senior Research | Profile | |
| Monique Silva | Senior Affairs | Profile | |
| James MD | Advisor | Profile | |
| Beth Mueller | Senior Resources | Profile | |
| Priya Raina | Senior Operations | Profile | |
| FAAD MBA | Chief Officer | Profile | |
| Daniel Faga | Interim Director | Profile | |
| MSc MBA | Advisory | Profile | |
| Dennis Mulroy | Chief Officer | Profile | |
| Douglas MBA | Senior CMC | Profile | |
| Marco Londei | Chief Medical Officer | Profile | |
| Eric Loumeau | General Counsel | Profile | |
| Benjamin Stone | Chief Officer | Profile |
About AnaptysBio Management Performance
The success or failure of an entity such as AnaptysBio often depends on how effective the management is. AnaptysBio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AnaptysBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AnaptysBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (1.86) | (1.95) |
The data published in AnaptysBio's official financial statements usually reflect AnaptysBio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AnaptysBio. For example, before you start analyzing numbers published by AnaptysBio accountants, it's critical to develop an understanding of what AnaptysBio's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AnaptysBio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AnaptysBio. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
AnaptysBio Workforce Analysis
Traditionally, organizations such as AnaptysBio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AnaptysBio within its industry.AnaptysBio Manpower Efficiency
Return on AnaptysBio Manpower
| Revenue Per Employee | 146.6K | |
| Revenue Per Executive | 714.9K | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 6.8M | |
| Working Capital Per Employee | 3.2M | |
| Working Capital Per Executive | 15.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.Note that the AnaptysBio information on this page should be used as a complementary analysis to other AnaptysBio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is AnaptysBio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.08) | Revenue Per Share 0.637 | Quarterly Revenue Growth 0.323 | Return On Assets (0.18) | Return On Equity (0.93) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.